Pub Date : 2019-05-01DOI: 10.1093/med/9780198840480.003.0003
A. Davies
Successful management of breakthrough pain depends on adequate assessment and adequate re-assessment. The assessment of pain primarily depends on basic clinical skills, that is, taking a detailed history and performing a thorough examination. Inadequate assessment may lead to ineffective or even inappropriate treatment. The objectives of assessment are to determine the aetiology and pathophysiology of the pain, and factors that indicate or contraindicate particular treatments. It is important to differentiate patients with uncontrolled background pain experiencing transient exacerbations of that pain, from patients with controlled background pain experiencing episodes of breakthrough pain. Inadequate reassessment may lead to the continuance of ineffective or inappropriate treatment. A number of different tools have been developed for the assessment of cancer-related pain. Those focusing on breakthrough pain include: the Breakthrough Pain Questionnaire, the Alberta Breakthrough Pain Assessment Tool, and the Breakthrough Pain Assessment Tool.
{"title":"Assessment","authors":"A. Davies","doi":"10.1093/med/9780198840480.003.0003","DOIUrl":"https://doi.org/10.1093/med/9780198840480.003.0003","url":null,"abstract":"Successful management of breakthrough pain depends on adequate assessment and adequate re-assessment. The assessment of pain primarily depends on basic clinical skills, that is, taking a detailed history and performing a thorough examination. Inadequate assessment may lead to ineffective or even inappropriate treatment. The objectives of assessment are to determine the aetiology and pathophysiology of the pain, and factors that indicate or contraindicate particular treatments. It is important to differentiate patients with uncontrolled background pain experiencing transient exacerbations of that pain, from patients with controlled background pain experiencing episodes of breakthrough pain. Inadequate reassessment may lead to the continuance of ineffective or inappropriate treatment. A number of different tools have been developed for the assessment of cancer-related pain. Those focusing on breakthrough pain include: the Breakthrough Pain Questionnaire, the Alberta Breakthrough Pain Assessment Tool, and the Breakthrough Pain Assessment Tool.","PeriodicalId":419187,"journal":{"name":"Cancer-related Breakthrough Pain","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116197624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-08-01DOI: 10.1093/MED/9780198840480.003.0004
A. Davies
Breakthrough pain is not a single entity, but a spectrum of very different entities. In most cases, the underlying cause of the pain is a direct effect of the cancer. There is emerging evidence to suggest certain oncological treatments may be effective in managing certain types of breakthrough pain. Optimal treatment of breakthrough pain depends on a variety of pain-related factors. Optimal treatment of breakthrough pain depends on a variety of patient-related factors. Avoidance or treatment of precipitating factors should be considered in patients with incident-type breakthrough pain. Movement-related/incident pain, secondary to metastatic bone disease, is a common phenomenon. Modification of the background analgesic regimen has been shown to be a useful approach in managing breakthrough pain. Multimodal approaches are often required. The cornerstone of the management of breakthrough pain episodes is the use of so-called rescue medication. The management of end-of-dose failure involves modification of the background analgesic regimen. The use of rescue medication depends on the type of breakthrough pain and acceptance depends on factors such as the route of administration of medication.
{"title":"General principles of management","authors":"A. Davies","doi":"10.1093/MED/9780198840480.003.0004","DOIUrl":"https://doi.org/10.1093/MED/9780198840480.003.0004","url":null,"abstract":"Breakthrough pain is not a single entity, but a spectrum of very different entities. In most cases, the underlying cause of the pain is a direct effect of the cancer. There is emerging evidence to suggest certain oncological treatments may be effective in managing certain types of breakthrough pain. Optimal treatment of breakthrough pain depends on a variety of pain-related factors. Optimal treatment of breakthrough pain depends on a variety of patient-related factors. Avoidance or treatment of precipitating factors should be considered in patients with incident-type breakthrough pain. Movement-related/incident pain, secondary to metastatic bone disease, is a common phenomenon. Modification of the background analgesic regimen has been shown to be a useful approach in managing breakthrough pain. Multimodal approaches are often required. The cornerstone of the management of breakthrough pain episodes is the use of so-called rescue medication. The management of end-of-dose failure involves modification of the background analgesic regimen. The use of rescue medication depends on the type of breakthrough pain and acceptance depends on factors such as the route of administration of medication.","PeriodicalId":419187,"journal":{"name":"Cancer-related Breakthrough Pain","volume":"150 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116211099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-08-01DOI: 10.1093/med/9780198840480.003.0008
A. Davies
Breakthrough pain is a heterogeneous condition. Non-opioid analgesics are a diverse group of drugs. Non-opioid analgesics may have a role in the management of breakthrough pain. Data on the use of most non-opioid analgesics is limited. Paracetamol and non-steroidal anti-inflammatory drugs are generally used as around-the-clock medication, although they may also be used as rescue medication. Systematic reviews of oral NSAIDs have confirmed benefits in cancer pain. Midazolam has been used in the treatment of refractory incident pain secondary to bone metastases and there is the potential for its use in the management of breakthrough pain secondary to muscle spasm. Ketamine is employed in anaesthetic doses in the management of procedural pain and in the management of predominantly non-malignant breakthrough pain. There is conflicting evidence for the use of nitrous oxide in the management of breakthrough pain.
{"title":"Non-opioid analgesics","authors":"A. Davies","doi":"10.1093/med/9780198840480.003.0008","DOIUrl":"https://doi.org/10.1093/med/9780198840480.003.0008","url":null,"abstract":"Breakthrough pain is a heterogeneous condition. Non-opioid analgesics are a diverse group of drugs. Non-opioid analgesics may have a role in the management of breakthrough pain. Data on the use of most non-opioid analgesics is limited. Paracetamol and non-steroidal anti-inflammatory drugs are generally used as around-the-clock medication, although they may also be used as rescue medication. Systematic reviews of oral NSAIDs have confirmed benefits in cancer pain. Midazolam has been used in the treatment of refractory incident pain secondary to bone metastases and there is the potential for its use in the management of breakthrough pain secondary to muscle spasm. Ketamine is employed in anaesthetic doses in the management of procedural pain and in the management of predominantly non-malignant breakthrough pain. There is conflicting evidence for the use of nitrous oxide in the management of breakthrough pain.","PeriodicalId":419187,"journal":{"name":"Cancer-related Breakthrough Pain","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129471831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-08-01DOI: 10.1093/med/9780198840480.003.0007
A. Davies
The intranasal and intrapulmonary routes are simple, do not necessarily require any specialized equipment, and can be used by both patients and their non-professional caregivers. Intranasal administration may be associated with rapid onset of analgesia. A number of fentanyl-based formulations are commercially available to manage breakthrough cancer pain. Intranasal opioids can be delivered by traditional spray bottles, and also by syringes fitted with atomisers. The intrapulmonary route has the potential for rapid onset of analgesia. and can be delivered by traditional nebulizers, and other inhalation devices (e.g. metered dose inhalers, dry powder inhalers). The transdermal route has less potential for rapid onset of analgesia. However, new patch technology (iontophoretic technology) may alter the current position.
{"title":"Intranasal and intrapulmonary opioids","authors":"A. Davies","doi":"10.1093/med/9780198840480.003.0007","DOIUrl":"https://doi.org/10.1093/med/9780198840480.003.0007","url":null,"abstract":"The intranasal and intrapulmonary routes are simple, do not necessarily require any specialized equipment, and can be used by both patients and their non-professional caregivers. Intranasal administration may be associated with rapid onset of analgesia. A number of fentanyl-based formulations are commercially available to manage breakthrough cancer pain. Intranasal opioids can be delivered by traditional spray bottles, and also by syringes fitted with atomisers. The intrapulmonary route has the potential for rapid onset of analgesia. and can be delivered by traditional nebulizers, and other inhalation devices (e.g. metered dose inhalers, dry powder inhalers). The transdermal route has less potential for rapid onset of analgesia. However, new patch technology (iontophoretic technology) may alter the current position.","PeriodicalId":419187,"journal":{"name":"Cancer-related Breakthrough Pain","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121972284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-08-01DOI: 10.1093/MED/9780198840480.003.0005
A. Davies
Rescue medication is taken as required, rather than on a regular basis. Oral opioids have a defined role in the management of breakthrough pain, but will only be effective if it is an opioid-responsive pain. Although the oral route is generally effective in the management of background pain, it is often less effective in the management of breakthrough pain. The ‘correct’ dose of rescue medication is the dose that provides maximal analgesia with minimal side effects. The pharmacokinetic profile of many orally delivered drugs does not mirror the temporal characteristics of many breakthrough pain episodes. The rectal administration of opioids is well established, although is now uncommon in day-to-day clinical practice. The intravenous route of administration is primarily used in secondary care settings. Intravenous/subcutaneous opioids provide rapid onset of analgesia, but are generally not practical in outpatient settings.
{"title":"Oral and parenteral opioids","authors":"A. Davies","doi":"10.1093/MED/9780198840480.003.0005","DOIUrl":"https://doi.org/10.1093/MED/9780198840480.003.0005","url":null,"abstract":"Rescue medication is taken as required, rather than on a regular basis. Oral opioids have a defined role in the management of breakthrough pain, but will only be effective if it is an opioid-responsive pain. Although the oral route is generally effective in the management of background pain, it is often less effective in the management of breakthrough pain. The ‘correct’ dose of rescue medication is the dose that provides maximal analgesia with minimal side effects. The pharmacokinetic profile of many orally delivered drugs does not mirror the temporal characteristics of many breakthrough pain episodes. The rectal administration of opioids is well established, although is now uncommon in day-to-day clinical practice. The intravenous route of administration is primarily used in secondary care settings. Intravenous/subcutaneous opioids provide rapid onset of analgesia, but are generally not practical in outpatient settings.","PeriodicalId":419187,"journal":{"name":"Cancer-related Breakthrough Pain","volume":"78 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114457988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-08-01DOI: 10.1093/MED/9780198840480.003.0009
A. Davies
Breakthrough pain is a heterogeneous condition. Non-pharmacological interventions include: rubbing/massage, application of heat, application of cold, distraction techniques, relaxation techniques, hypnotherapy/hypnosis, transcutaneous electrical nerve stimulation (TENS), and acupuncture. But most of these have not been subject to rigorous study. Anaesthetic interventions are usually utilized in patients with uncontrolled background pain, but they are sometimes used in patients with uncontrolled breakthrough pain. A variety of different techniques are available. Peripheral (local anaesthetic) nerve blockade and neuraxial analgesia delivery may be used. Non-surgical stabilization, surgical stabilization, corticosteroid instillation, alcohol instillation, phenol instillation, cryoablation, radiofrequency ablation, laser ablation, cementoplasty/vertebroplasty, balloon kyphoplasty, and MR-guided focused ultrasound surgery are other strategies, most of which have not been subject to rigorous scientific investigation. Non-opioid analgesics are a diverse group of drugs. Non-opioid analgesics may have a role in the management of breakthrough pain. Data on the use of most non-opioid analgesics is limited.
{"title":"Other therapeutic interventions","authors":"A. Davies","doi":"10.1093/MED/9780198840480.003.0009","DOIUrl":"https://doi.org/10.1093/MED/9780198840480.003.0009","url":null,"abstract":"Breakthrough pain is a heterogeneous condition. Non-pharmacological interventions include: rubbing/massage, application of heat, application of cold, distraction techniques, relaxation techniques, hypnotherapy/hypnosis, transcutaneous electrical nerve stimulation (TENS), and acupuncture. But most of these have not been subject to rigorous study. Anaesthetic interventions are usually utilized in patients with uncontrolled background pain, but they are sometimes used in patients with uncontrolled breakthrough pain. A variety of different techniques are available. Peripheral (local anaesthetic) nerve blockade and neuraxial analgesia delivery may be used. Non-surgical stabilization, surgical stabilization, corticosteroid instillation, alcohol instillation, phenol instillation, cryoablation, radiofrequency ablation, laser ablation, cementoplasty/vertebroplasty, balloon kyphoplasty, and MR-guided focused ultrasound surgery are other strategies, most of which have not been subject to rigorous scientific investigation. Non-opioid analgesics are a diverse group of drugs. Non-opioid analgesics may have a role in the management of breakthrough pain. Data on the use of most non-opioid analgesics is limited.","PeriodicalId":419187,"journal":{"name":"Cancer-related Breakthrough Pain","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126709626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-08-01DOI: 10.1093/MED/9780198840480.003.0006
A. Davies
The oral transmucosal routes are buccal and sublingual. The absorption of drugs across the oral mucosa involves a process of passive absorption, and may involve either the transcellular route or the paracellular route. A number of drug factors affect the absorption of drugs across the oral mucosa. Oral transmucosal drug delivery does not require expertise, preparation, or technical equipment. Oral transmucosal administration may be associated with rapid onset of analgesia. A number of fentanyl-based formulations are commercially available to manage breakthrough cancer pain. A variety of other opioids have been subject to oral transmucosal administration. However, many of these opioids are not very lipophilic and, therefore, not suited for buccal or sublingual administration. Some of the more successful ones are alfentanil and sufentanil.
{"title":"Oral transmucosal opioids","authors":"A. Davies","doi":"10.1093/MED/9780198840480.003.0006","DOIUrl":"https://doi.org/10.1093/MED/9780198840480.003.0006","url":null,"abstract":"The oral transmucosal routes are buccal and sublingual. The absorption of drugs across the oral mucosa involves a process of passive absorption, and may involve either the transcellular route or the paracellular route. A number of drug factors affect the absorption of drugs across the oral mucosa. Oral transmucosal drug delivery does not require expertise, preparation, or technical equipment. Oral transmucosal administration may be associated with rapid onset of analgesia. A number of fentanyl-based formulations are commercially available to manage breakthrough cancer pain. A variety of other opioids have been subject to oral transmucosal administration. However, many of these opioids are not very lipophilic and, therefore, not suited for buccal or sublingual administration. Some of the more successful ones are alfentanil and sufentanil.","PeriodicalId":419187,"journal":{"name":"Cancer-related Breakthrough Pain","volume":"176 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132797244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：